**Diffuse Large B-Cell**

- **Previously Treated**
  - **>1 Relapse**
    - **MATCH Screening**
      - **No Mutation Match**
        - **Not Chemorefractory**
          - **LYMNH0139**
            - Phase I/II
            - Hu5F9-G4 in Combo w/ Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
            - PI: Advani Forty Seven Inc.
          - **LYMNH0157**
            - Phase III
            - CYT-9851 (Oral RAD51 Inhibitor) in Relapsed/Refractory A-Cell Malignancies & Solid Tumors
            - PI: Advani Cytelir
      - **Chemorefractory**
        - **LYMNH0157**
          - Phase III
          - CYT-9851 (Oral RAD51 Inhibitor) in Relapsed/Refractory A-Cell Malignancies & Solid Tumors
          - PI: Advani Cytelir
          - **ECOG-ACRIN EAY131**
            - Molecular Analysis for Therapy Choice (MATCH)
            - PI: Ford ECOG-ACRIN
- **Untreated**
  - **Age ≥75**
    - **ECOG-ACRIN S-1918**
      - Phase II/III
      - R-MiniCHOP +/- CC-486 in New Dx DLBCL Follicular /Transformed /B-Cell Lymphomas
      - PI: Advani Pending

**KEY**
- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Extension Study
- Immunotherapy
- Link
- Trial Posting
- Enrollment on Hold

**Please mark up a copy using black ink and email changes to SRC-office@stanford.edu**